Status:
COMPLETED
Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)
Lead Sponsor:
Fundacion CRIS de Investigación para Vencer el Cáncer
Collaborating Sponsors:
Amgen
Conditions:
Immune Thrombocytopenia
Myelodysplastic Syndromes
Eligibility:
All Genders
18+ years
Brief Summary
Current diagnostic criteria for Immune ThrombocytoPenia (ITP) are mainly based on the presence of low numbers of platelets, excluding other multiple causes of thrombocytopenia, including immunodeficie...
Eligibility Criteria
Inclusion
- Patients aged ≥ 18 years old at diagnosis
- Informed consent in writing
- Newly diagnosed primary ITP patients, or
- Newly diagnosed MDS patients
Exclusion
- Patients who participated in a interventional thrombopoietin receptor agonists (TPO-RA) clinical trial since TPO-RA treatment initiation
- Patients with secondary immune thrombopenia
Key Trial Info
Start Date :
April 25 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 19 2021
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT03469661
Start Date
April 25 2018
End Date
April 19 2021
Last Update
August 18 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Complejo Hospitalario de A Coruña
A Coruña, Spain
2
Hospital de Burgos
Burgos, Spain
3
Hospital Universitario Insular de Gran Canaria
Las Palmas de Gran Canaria, Spain
4
Hospital Ramon y Cajal
Madrid, Spain